[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Kwon EJ, Kim SW, Kim KK, Seo HS, Kim DY: A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat; 2009 Mar;41(1):53-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-year-old female receiving gemcitabine and cisplatin chemotherapy for stage IV gallbladder cancer developed the clinicoradiologic syndrome, posterior reversible encephalopathy syndrome (PRES).
  • Just before the 4th gemcitabine chemotherapy cycle, she was admitted to the hospital with complaints of headache, dizziness, and generalized tonic-clonic seizures.
  • A MRI was performed on the day when the seizure developed, and the findings showed patchy cortical and subcortical T2 hyperintensity without enhancement that involved both occipital and parietal lobes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2007 Nov;12(11):1332-5 [18055853.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2484-6 [17557962.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):e48 [17008686.001]
  • [Cites] Neuroradiology. 2005 Aug;47(8):586-90 [15997391.001]
  • [Cites] J Korean Med Sci. 1999 Feb;14(1):89-92 [10102531.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):415-7 [9541291.001]
  • [Cites] Radiographics. 1998 Mar-Apr;18(2):353-67 [9536483.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):494-500 [8559202.001]
  • [Cites] Lancet. 1992 Aug 22;340(8817):496 [1354830.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):679-93 [1648599.001]
  • [Cites] Acta Oncol. 2004;43(6):590-1 [15370618.001]
  • [Cites] J Korean Med Sci. 2001 Jun;16(3):328-34 [11410695.001]
  • [Cites] Magn Reson Imaging. 2001 Jan;19(1):129-32 [11295355.001]
  • (PMID = 19688073.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2699096
  • [Keywords] NOTNLM ; Cisplatin / Gemcitabine / Posterior reversible encephalopathy syndrome (PRES)
  •  go-up   go-down


2. Mody K, Strauss E, Lincer R, Frank RC: Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer; 2010;10:570
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.
  • BACKGROUND: Gallbladder cancer typically follows an aggressive course, with chemotherapy the standard of care for advanced disease; complete remissions are rarely encountered.
  • The epidermal growth factor receptor (EGFR) is a promising therapeutic target but the activity of single agent oral EGFR tyrosine kinase inhibitors is low.
  • There have been no previous reports of chemotherapy plus an EGFR-tyrosine kinase inhibitor (TKI) to treat gallbladder cancer or correlations of response with the mutation status of the tyrosine kinase domain of the EGFR gene.
  • CASE PRESENTATION: A 67 year old man with metastatic gallbladder cancer involving the liver and abdominal lymph nodes was treated with gemcitabine (1000 mg/m2) on day 1 and 8 every 21 days as well as daily erlotinib (100 mg).
  • After four cycles of therapy, the CA 19-9 normalized and a PET/CT showed a complete remission; this response was maintained by the end of 12 cycles of therapy.
  • Gemcitabine was then discontinued and single agent erlotinib was continued as maintenance therapy.
  • The disease remains in good control 18 months after initiation of therapy, including 6 months on maintenance erlotinib.
  • This disclosed the wild-type genotype with no mutations found.
  • CONCLUSION: This case report demonstrates a patient with stage IV gallbladder cancer who experienced a rarely encountered complete, prolonged response after treatment with an oral EGFR-TKI plus chemotherapy.
  • These observations should inform the design of clinical trials using EGFR-TKIs to treat gallbladder and other biliary tract cancers; such trials should not select patients based on EGFR mutation status.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / genetics. Mutation. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. CA-19-9 Antigen / biosynthesis. DNA Mutational Analysis. Erlotinib Hydrochloride. Exons. Humans. Lymphatic Metastasis. Male. Positron-Emission Tomography / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2010 Jan;11(1):48-54 [19932054.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1237-45 [16078261.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5 [16234545.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):649-52 [16032426.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1680-5 [16551849.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] BMC Cancer. 2006;6:190 [16846514.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] Oncologist. 2010;15(2):168-81 [20147507.001]
  • (PMID = 20961434.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CA-19-9 Antigen; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2972285
  •  go-up   go-down


3. Julka PK, Puri T, Rath GK: A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int; 2006 Feb;5(1):110-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
  • BACKGROUND: Patients with carcinoma of the gallbladder have advanced, unresectable tumor at the time of presentation and face a dismal prognosis in the absence of a standard palliative chemotherapy regimen.
  • This study was undertaken to evaluate the efficacy and safety of combined chemotherapy of gemcitabine and carboplatin in 20 patients with advanced gallbladder carcinoma.
  • METHODS: The criteria of eligibility included chemonaive patients with unresectable gallbladder cancer, bidimensionally measurable disease, Zubrod's performance status < or = 2, and adequate major organ function.
  • RESULTS: In this group of 20 patients with advanced gallbladder carcinoma 6 were men and 14 women, with a median age of 55 years.
  • The stage of the tumor at presentation was IVB in 14 patients (70%), IVA in 3 (15%) and III in 3 (15%).
  • The median time to progression of the tumor was 33.8 weeks, and 1-year survival rate of the patients was 43.3%.
  • Anemia of WHO grade III or IV was seen in 2 patients (10%) and 1 patient (5%), respectively.
  • CONCLUSION: With mild toxicity, combined chemotherapy of gemcitabine and carboplatin is effective in the treatment of advanced gallbladder carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16481295.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Wang BL, Zhai HY, Chen BY, Zhai SP, Yang HY, Chen XP, Zhao WT, Meng L: Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat Dis Int; 2004 May;3(2):296-9
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relationship between MDR1 gene and gallbladder cancer.
  • BACKGROUND: The most common mechanisms of multidrug resistance (MDR) in cancer cells is the expression of an energy-dependent exfflux pump.
  • It is a major therapeutic problem in cancer chemotherapy.
  • The aim of this study is to study the expression of MDR1 gene encoding P-gp and MDRl mRNA in primary gallbladder carcinoma, and analyze its clinical significance.
  • METHODS: Immunohistochemistry (IHC) S-P method and in situ polymerase chain reaction (ISPCR) were used to detect the expression of P-gp and MDR1 mRNA in 53 cases of untreated primary gallbladder carcinoma and 12 cases of cholecystitis (archival paraffin-embedded tissues).
  • The positive expression rate of P-gp and MDR1mRNA were 69.44%, 83.33% and 41.18%, 47.06% respectively in tissues in stage of Nevin I-III against Nevin IV, V (P<0.05).
  • In well, moderately differentiated gallbladder carcinoma tissues, their expressions were 79.49%, 69.23% against 50.00%, 35.71% in low, undifferentiated tissues (P<0.05).
  • CONCLUSIONS: MDR to gallbladder carcinoma is closely related to the intrinsic MDR and it provides an important evidence to reverse the MDR by detection of the MDR1 gene.
  • Meanwhile, MDR1 gene expression in gallbladder carcinoma is correlated with some biological characteristics, takes part in the carcinogenesis of gallbladder tissues, and acts as a valuable biomarker of prognosis.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma / genetics. Gallbladder Neoplasms / genetics. Genes, MDR / genetics. P-Glycoprotein / genetics
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15138130.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 0 / RNA, Messenger
  •  go-up   go-down


5. Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ: Adjuvant radiation therapy in gall bladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther; 2006 Apr-Jun;2(2):52-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiation therapy in gall bladder cancers: 10 years experience at Tata Memorial Hospital.
  • Although these are considered radio-resistant, adjuvant radiation, with or without chemotherapy, has been tried to improve loco-regional control and overall survival rates.
  • With an aim to evaluate the natural history of gall bladder cancers, role of radiation therapy (RT) and prognostication, a retrospective analysis was undertaken.
  • MATERIALS AND METHODS: Between 1991-2000, 60 patients with gall bladder cancer, treated with radical intent, were evaluated.
  • The details of post-operative adjuvant treatment, including radiation therapy details, as well as chemotherapeutic agents, number of cycles and type of infusion [bolus/infusion], were noted.
  • On histopathological staging, 28 patients (46.5%) had stage II, 19 (32%) had stage III, 12 (20%) had stage-I and 1 patient had stage IV disease.
  • Thirteen (21%) patents did not receive any adjuvant treatment, 32 (53%) patients received adjuvant RT alone, 8(14%) received post-operative CT+RT and 7 (12%) patients received CT alone.
  • Stage grouping ('P' = 0.007), Pathological T ('P' = 0.01) had significant impact on DFS on univariate analysis, where as histological grade ('P' = 0.06) showed trend towards significance.
  • Early diagnosis and curative surgery, followed by appropriate adjuvant radiation therapy, may improve survivals, with no established consensus till date.
  • Following curative surgery, pathological T stage and stage grouping, are the significant prognostic factors for outcome.
  • [MeSH-major] Gallbladder Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Surgical Procedures. Humans. India. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998675.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Endo I, Shimada H: [Present situation of and prospects for standardization of surgery for biliary tract cancer]. Nihon Geka Gakkai Zasshi; 2003 May;104(5):404-11
Genetic Alliance. consumer health - Biliary Tract Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Present situation of and prospects for standardization of surgery for biliary tract cancer].
  • Surgery remains the primary treatment for biliary tract malignancies.
  • A standard therapy is required in the era of evidence-based medicine.
  • However, guidelines for biliary tract cancer surgery have not yet been adopted.
  • We review the current literature on the treatment of biliary tract malignancies and surveyed the prospects for standardization of biliary tract cancer surgery.
  • For patients with gallbladder cancer, surgical procedures should be selected based on the depth of invasion.
  • In aggressive surgery for stage IV gallbladder cancer, attention should be paid to the high incidence of operative mortality.
  • For Bismuth types III and IV, hepatectomy combined with caudate lobectomy appears to be the standard surgery.
  • Pancreatoduodenectomy is considered the standard procedure for middle and lower bile duct and ampullary cancer.
  • It is necessary to continue developing adjuvant therapies for patients with negative prognostic factors.
  • The appropriateness of adjuvant therapies such as chemotherapy and radiation therapy should be confirmed in further clinical trials.
  • It is necessary to reach a definite consensus on standard therapy for biliary tract malignancies in the near future, and therefore multicenter, randomized trials to address the issues involved should be initiated in Japan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12774525.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Malik IA, Aziz Z, Zaidi SH, Sethuraman G: Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol; 2003 Apr;26(2):174-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
  • We evaluated the efficacy and toxicity of gemcitabine with or without cisplatin in 11 chemonaive patients with histologically confirmed advanced gallbladder cancer.
  • All were symptomatic and had stage IV disease.
  • Treatment cycles were repeated every 21 days.
  • One patient (9%) had complete remission of disease and 6 (55%) achieved a partial response to chemotherapy with an overall response rate of 64%.
  • Median time to progression was 28 weeks and median overall survival was 42 weeks.
  • Toxicity was easily manageable, and no treatment-related deaths occurred.
  • We conclude that gemcitabine in combination with cisplatin may be one of the most effective therapies for patients with advanced gallbladder cancer.
  • If confirmed by others, it may provide an important therapeutic option in managing these patients who otherwise have a dismal prognosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Female. Humans. Male. Middle Aged. Prospective Studies. Remission Induction. Survival Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714891.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Medina-Franco H, Ramos-Gallardo G, Orozco-Zepeda H, Mercado-Díaz MA: [Prognostic factor in gallbladder cancer]. Rev Invest Clin; 2005 Sep-Oct;57(5):662-5
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor in gallbladder cancer].
  • [Transliterated title] Factores pronósticos en cáncer de vesícula.
  • BACKGROUND: Gallbladder cancer is a rare and aggressive neoplasm.
  • OBJECTIVE: The purpose of this manuscript was to evaluate the prognostic factors associated with overall survival in gallbladder cancer patients.
  • METHODS: We performed a retrospective study of the patients with gallbladder cancer who received attention in a tertiary referral center in Mexico City during a 13 year period (1990-2002).
  • We evaluated demographic, clinical, pathological and treatment variables.
  • Eighty-six percent were found to have stage IV.
  • On univariate analysis surgery, early stage, chemotherapy, Karnofsky 2 80 and serum albumin > 3.0 g/dL were associated with better prognosis.
  • CONCLUSIONS: Most cases of gallbladder cancer presented with advanced stage.
  • [MeSH-major] Gallbladder Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419459.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


9. Sasson AR, Hoffman JP, Ross E, Meropol NJ, Szarka CE, Freedman G, Pinover W, Pingpank JF, Eisenberg BL: Trimodality therapy for advanced gallbladder cancer. Am Surg; 2001 Mar;67(3):277-83; discussion 284
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality therapy for advanced gallbladder cancer.
  • We conducted a retrospective review of all patients who underwent surgical extirpation for stage III, stage IV, or recurrent carcinoma of the gallbladder.
  • Between 1991 and 1999 ten patients underwent surgical resection for advanced gallbladder cancer.
  • All patients received adjuvant therapy either pre- or postoperatively.
  • Radiotherapy was used in all patients and chemotherapy in 90 per cent of patients.
  • An additional patient with stage II disease initially was also treated surgically for a local recurrence.
  • Surgical management involved cholecystectomy and resection of various amounts of liver surrounding the gallbladder bed and regional lymphadenectomy.
  • We conclude that trimodality therapy in selected patients with stage III, IV, or recurrent carcinoma of the gallbladder is possible and may result in prolonged survival.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Cholecystectomy. Gallbladder Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Acute Disease. Aged. Chemotherapy, Adjuvant. Cholecystitis / etiology. Chronic Disease. Female. Humans. Jaundice / etiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11270889.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D: Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys; 2002 Jan 1;52(1):167-75
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.
  • PURPOSE: This study was performed to evaluate the outcome of patients with gallbladder cancer who received postoperative concurrent chemotherapy and radiation therapy.
  • METHODS AND MATERIALS: Curative resection followed by adjuvant combined modality therapy with external beam radiation therapy (EBRT) and chemotherapy was attempted in 21 consecutive gallbladder carcinoma (GBC) patients at the Mayo Clinic from 1985 through 1997.
  • EBRT fields encompassed the tumor bed and regional lymph nodes (median dose of 54 Gy in 1.8-2.0-Gy fractions).
  • One patient received 15 Gy intraoperatively after EBRT.
  • One patient had Stage I disease, and 20 had Stage III-IV disease.
  • The 5-year survival rate of patients with Stage I-III disease was 65% vs. 0% for those with Stage IV disease (p < 0.02).
  • Five-year local control rates were 100% for the 6 patients who received total EBRT doses >54 Gy (microscopic residual, 3 patients; gross residual, 1 patient; negative but narrow margins, 2 patients) vs. 65% for the 15 who received a lower dose (3, gross residual; 2, microresidual; 10, negative margins).
  • CONCLUSION: Patients with completely resected (negative margins) GBC followed by adjuvant EBRT plus 5-fluorouracil chemotherapy had a relatively favorable prognosis, with a 5-year survival rate of 64%.
  • Both tumor stage and extent of resection seemed to influence survival and local control.
  • More aggressive measures using current cancer therapies and integration of new cancer treatment modalities will be required to favorably impact on the poor prognosis of patients with Stage IV or subtotally resected GBC.
  • [MeSH-major] Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11777635.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Misra MC, Guleria S: Management of cancer gallbladder found as a surprise on a resected gallbladder specimen. J Surg Oncol; 2006 Jun 15;93(8):690-8
MedlinePlus Health Information. consumer health - Gallbladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cancer gallbladder found as a surprise on a resected gallbladder specimen.
  • Carcinoma gallbladder is associated with an overall 5-year survival rate reported less than 5% due to late diagnosis.
  • Advent of ultrasound scanning may help in detecting gallbladder polyps and an early gallbladder cancer.
  • Excellent 5-year survival (up to 100%) has been reported for Stage Ia disease and the survival has significantly improved for Stage Ib, II, and III if appropriate re-operation is carried out soon after the incidental detection of gallbladder cancer.
  • Laparoscopic cholecystectomy (LC) is contraindicated in the presence of gallbladder cancer.
  • It is recommended to excise all laparoscopic port sites, at the time of re-operation.
  • Re-operation for Stage II gallbladder cancer is associated with a 90-100% 3-year survival rate.
  • Patients with Stage III and IV tumors also benefit from an extended cholecystectomy.
  • It is advantageous to perform the appropriate extent of surgery for gallbladder cancer at the initial operation.
  • Heightened awareness of the presence of cancer and the knowledge of appropriate management are important.
  • For patients whose cancer is an incidental finding on pathologic review, re-resection is indicated for all disease except Stage Ia.
  • Radiotherapy and chemotherapy have not been found effective as an adjuvant or palliative therapy in gallbladder cancer.
  • [MeSH-major] Cholecystectomy, Laparoscopic. Gallbladder Diseases / surgery. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / surgery
  • [MeSH-minor] Cholecystectomy. Gallbladder / pathology. Gallbladder / ultrasonography. Hepatectomy. Humans. Incidental Findings. Laparoscopy. Lymph Node Excision. Neoplasm Staging. Polyps / epidemiology. Polyps / ultrasonography. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16724357.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


12. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any.
  • METHODS: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV.
  • These participants did not receive any other conventional or investigational cancer treatments.
  • The participants report no side effects from the drug psorinum.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.
  • Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Misra S, Chaturvedi A, Misra NC: Gallbladder cancer. Curr Treat Options Gastroenterol; 2006 Apr;9(2):95-106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder cancer.
  • Gallbladder cancer (GBC) is the most common malignancy of the biliary tract and the fifth most common gastrointestinal (GI) cancer.
  • Most GBC presents clinically as advanced disease with unfavorable prognosis and poor response to treatment.
  • Such patients are generally in an earlier stage of disease and are potentially more curable by a completion radical cholecystectomy, which is especially indicated for patients whose disease is stage pT1b or beyond.
  • Radical surgery is the mainstay of curative intent treatment for GBC.
  • When feasible, extended or radical cholecystectomy is the standard treatment for resectable GBC.
  • Patients with advanced stage III or IV disease may undergo more complex, high-risk, and morbid extended resections such as hepatopancreaticoduodenectomy.
  • Patients not fit for such major resection or found unresectable on imaging or exploration are usually offered palliative treatment.
  • This may be in the form of surgical palliation (eg, palliative bypass for gastric outlet, bowel, or biliary tract obstruction), endoscopic biliary stenting (for obstructive jaundice), or palliative chemotherapy.
  • Chemotherapy for GBC is generally used in the palliative setting.
  • Patients with advanced GBC and jaundice who undergo stenting followed by chemotherapy show response and survival rates similar to those who present without jaundice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):167-75 [11777635.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Am Surg. 2001 Nov;67(11):1041-7 [11730220.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):423-7 [9690533.001]
  • [Cites] Eur J Surg Oncol. 2000 Mar;26(2):164-7 [10744937.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1689-700 [14534886.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):948-55 [11020856.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):639-46 [8916879.001]
  • [Cites] Hepatogastroenterology. 1991 Apr;38(2):170-5 [1649788.001]
  • [Cites] Br J Surg. 2001 May;88(5):675-8 [11350438.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):351-6 [12201499.001]
  • [Cites] Semin Surg Oncol. 2000 Sep-Oct;19(2):145-55 [11126379.001]
  • [Cites] World J Surg. 2002 Jul;26(7):867-71 [11960212.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(6):518-24 [11956902.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):167-76 [12623362.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1300-7 [8826954.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):438-43 [11016462.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3375-80 [11705850.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Eur J Surg. 1997 Jun;163(6):419-26 [9231853.001]
  • [Cites] Chemotherapy. 2003 Jun;49(3):154-8 [12815209.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1192-6 [12181241.001]
  • [Cites] Surg Gynecol Obstet. 1978 Dec;147(6):929-42 [362580.001]
  • [Cites] J Clin Oncol. 1996 Aug;14 (8):2311-5 [8708722.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):478-83 [14998852.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1516-20 [15083178.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1271-6; discussion 1277 [11071474.001]
  • [Cites] Br J Surg. 1994 Nov;81(11):1655-7 [7827897.001]
  • [Cites] CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64 [11760569.001]
  • [Cites] World J Surg. 1991 May-Jun;15(3):337-43 [1853612.001]
  • [Cites] World J Surg. 2003 Mar;27(3):266-71 [12607049.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):179-84 [11856130.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):695-706 [15343276.001]
  • [Cites] Adv Surg. 2001;35:1-20 [11579805.001]
  • [Cites] Cancer. 1977 Apr;39(4):1425-9 [192431.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):83-9; discussion 89 [14746839.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):45-52 [15642425.001]
  • [Cites] J Am Coll Surg. 2001 May;192(5):600-7 [11333097.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):758-63 [7571677.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1030-4 [15990005.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):557-69 [10998654.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):14-9 [9496479.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8):1049-59; discussion 1060, 1065-6, 1068 [15328897.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):385-94 [15729060.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Ann Surg. 1994 Mar;219(3):275-80 [8147608.001]
  • (PMID = 16539870.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, D'Angelica M, Dematteo RP, Blumgart LH, O'Reilly EM: Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol; 2008 Dec 1;98(7):485-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
  • BACKGROUND: The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000.
  • This report examines the patterns of presentation, adjuvant treatment and survival of a large cohort of patients with GBC evaluated at MSKCC over a 10-year period.
  • Patients were identified from the MSKCC cancer registry.
  • Information extracted included, demographics, clinical and pathological stage, surgical management, pathology, adjuvant and palliative therapy, date of relapse, death or last follow-up.
  • 36.6% presented as AJCC Stage IV.
  • Of those who underwent curative resections (N = 123), 8 (6.5%) received adjuvant chemotherapy, 8 (6.5%) chemoradiation alone and 8 (6.5%) both chemoradiation and systemic chemotherapy.
  • The median survival for those presenting with stage Ia-III disease was 12.9 months (95% CI 11.7-15.8 months) and 5.8 months (95% CI 4.5-6.7) for those presenting with stage IV disease.
  • The median survival for those who received adjuvant therapy was 23.4 months (95% CI 15.7-47).
  • Although we did not observe a survival benefit for those who received adjuvant therapy, the study did not have sufficient power to address this question.
  • In addition, the number of patients who received adjuvant therapy was small with marked heterogeneity in clinical and therapeutic details, precluding any definitive conclusions being drawn.
  • Prospective randomized trials of adjuvant therapy are needed in this disease.
  • [MeSH-major] Gallbladder Neoplasms / mortality. Gallbladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Capecitabine. Chemotherapy, Adjuvant. Cholecystectomy. Cholecystectomy, Laparoscopic. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Hepatectomy. Humans. Incidental Findings. Male. Middle Aged. Neoplasm, Residual. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / mortality. Sarcoma / pathology. Sarcoma / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18802958.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Malik IA, Aziz Z: Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder. Am J Clin Oncol; 2003 Apr;26(2):124-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder.
  • We evaluated the efficacy and toxicity of 5-fluorouracil (5-FU) and folinic acid (Mayo Clinic regimen) in previously untreated patients with advanced gallbladder cancer.
  • Thirty patients with histologically confirmed adenocarcinoma of gallbladder were enrolled on this trial.
  • All were symptomatic and had stage IV disease.
  • Treatment cycles were repeated every 28 days.
  • Only two patients (7%) achieved an objective response to therapy.
  • Median time to progression was 4.7 months, and median overall survival was 14.8 months.
  • Toxicity was moderate, and one treatment-related death occurred.
  • In conclusion, 5-FU and folinic acid (Mayo Clinic regimen) is ineffective in the management of patients with advanced gallbladder cancer, and further trials with this regimen are not recommended.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Gallbladder Neoplasms / drug therapy. Leucovorin / therapeutic use

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714880.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Takayanagi N, Chiba H, Sagawa T, Hirayama Y, Tsuji Y, Sakamaki S: [A case of inoperable advanced gallbladder cancer that has maintained stable disease status for a long period with gemcitabine and cisplatin therapy]. Gan To Kagaku Ryoho; 2004 Mar;31(3):439-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inoperable advanced gallbladder cancer that has maintained stable disease status for a long period with gemcitabine and cisplatin therapy].
  • We report a case of inoperable advanced gallbladder cancer that responded to treatment with gemcitabine (GEM) and cisplatin (CDDP) therapy.
  • A 54-year-old woman was diagnosed in a nearby hospital with inoperable advanced gallbladder cancer (T4, N1, H0, P1, M(-): Stage IV b) with direct invasion to the liver.
  • Therefore, chemotherapy was performed by TS-1.
  • Two months later, however, the disease was found to have progressed, and she was referred to our hospital for further therapy.
  • Combined chemotherapy with GEM 1,000 mg/m2 on days 1, 8 and 15 and CDDP 50 mg/m2 on day 1 was performed starting in June 2002.
  • No side effects were observed after the first administration during hospitalization, so the treatment was continued on an outpatient basis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Quality of Life. Survivors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045958.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Malik IA: Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases. J Gastroenterol Hepatol; 2003 Aug;18(8):950-3
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases.
  • BACKGROUND AND AIMS: Gallbladder cancer is common in Pakistan and has an extremely poor prognosis.
  • Treatment is primarily surgical.
  • Chemotherapy is frequently used in patients with advanced disease.
  • This study was performed to evaluate and compare the clinicopathological features and management of gallbladder cancer in Pakistani patients, with particular emphasis on factors that influence survival.
  • METHODS: Two hundred and thirty-three patients with histologically proven gallbladder cancer were studied.
  • Information was prospectively collected on demographic features, clinical and laboratory findings at the time of presentation, influence of therapy, and survival.
  • The majority (69%) had a history of symptomatic gallbladder disease.
  • Stage (P < 0.001), jaundice (P = 0.01) and palpable mass (P = 0.02) were statistically significant variables.
  • However, on multivariate analysis, tumor node metastases (TNM) stage was the only factor influencing survival.
  • Median survival of the patients was 44 months for patients with stage I disease, 23 months for stage II, 17 months for stage III and 6 months for stage IV.
  • Most patients presented at an advanced stage of disease and had an extremely poor prognosis.
  • Systemic therapy did not provide any survival benefit.
  • The TNM stage remains the most important factor influencing survival.
  • [MeSH-major] Adenocarcinoma / therapy. Gallbladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859725.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


18. Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, Zheng H, Lauwers GY, Ferrone CR: Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg; 2009 May;144(5):441-7; discussion 447
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience.
  • OBJECTIVES: To determine the prevalence of incidentally found cases of gallbladder cancer, the incidence of residual disease at reexploration, and the changes in the mode of presentation, treatment, and survival of patients with gallbladder cancer during a period of more than 4 decades.
  • PATIENTS: Between January 1, 1962, and March 1, 2008, 402 patients with gallbladder cancer were identified and their clinicopathologic data were analyzed.
  • INTERVENTIONS: Surgical treatment, radiotherapy, and chemotherapy.
  • MAIN OUTCOME MEASURES: Incidentally discovered gallbladder cancer, incidence of residual disease, and differences in presentation, treatment, and survival.
  • Between January 1, 1994, and March 1, 2008, 6881 laparoscopic cholecystectomies were performed, and there were 17 incidentally discovered cases of gallbladder cancer (0.25%).
  • Patients with stage IV disease (34 [13.1%] diagnosed from 1962-1979; 34 [13.1%] diagnosed from 1980-1997; and 22 [8.5%] diagnosed from 1998-2008) had a median survival of 4 months (range, 0-37 months).
  • Cox regression analysis identified T stage and surgical margin status as significant prognostic factors.
  • CONCLUSIONS: Gallbladder cancer is incidentally found during 0.25% of laparoscopic cholecystectomies.
  • As T stage increases, the likelihood of residual disease on reexploration increases.
  • Although many patients with gallbladder cancer present with incurable disease and have very poor survival, the overall prognosis is improving, likely because of more extensive operations.
  • [MeSH-major] Gallbladder Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Child. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm, Residual / epidemiology. Neoplasm, Residual / therapy. Proportional Hazards Models. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451486.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mori Y, Katsumata K, Tokita H, Kato F, Yamamoto J, Tsuchida A, Aoki T: [A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1485-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy].
  • The patient was a 70-year-old man who in November 2000 had undergone pancreatoduodenectomy for a diagnosis of lower bile duct cancer by his previous physician.
  • Left cervical and intra-abdominal lymph node enlargement were detected at 3 years 4 months postoperatively, and a biopsy resulted in a histopathological diagnosis of metastasis by bile duct cancer.
  • S-1/CDDP therapy seemed to be capable of serving as a useful treatment for gallbladder and bile duct cancer in the future.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Humans. Lymphatic Metastasis / pathology. Male. Oxonic Acid / administration & dosage. Pancreaticoduodenectomy. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876152.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS: Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie; 2010;33(1-2):45-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
  • BACKGROUND: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies.
  • The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract cancer.
  • CASE REPORTS: We retrospectively analyzed the outcomes of 5 biliary tract cancer patients receiving cetuximab-containing therapy.
  • Four of them had stage IV disease, and 1 patient had incomplete resection at the time of diagnosis.
  • After cetuximab treatment, complete response was achieved in 1 patient, partial response in 3 patients, and stable disease in 1 patient.
  • Only 1 surgical specimen was adequate for K-ras mutation test, and the wild type was confirmed.
  • Complete response was found in the patient who had wild type K-ras.
  • CONCLUSIONS: Cetuximab-containing therapy might be an effective treatment for advanced biliary tract cancer.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cetuximab. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2010;33(1-2):10-1 [20164655.001]
  • (PMID = 20164661.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Niinobu T, Nakagawa S, Itani Y, Nishikawa Y, Amano M, Higaki N, Hayashida H, Sakon M: [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1761-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy].
  • The patient, a 40-year-old woman, underwent total gastrectomy and excision of the pancreatic tail, spleen and gallbladder for gastric cancer in September 2000.
  • The lesion was judged to be P1, SE, H0, N2 and Stage IV and the patient was managed on a regular schedule as an outpatient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Diseases / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cholecystectomy. Cisplatin / administration & dosage. Constriction, Pathologic. Drug Combinations. Female. Gastrectomy. Humans. Oxonic Acid / administration & dosage. Pancreatectomy. Pyridines / administration & dosage. Splenectomy. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Shimada Y, Matsumoto G, Baba H, Tsurta K, Okamoto A: [Two cases of advanced gallbadder cancer with para-aortic lymph node metastasis responding to intra-aortic infusion of gemcitabine and low-dose CDDP/5-FU]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1347-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced gallbadder cancer with para-aortic lymph node metastasis responding to intra-aortic infusion of gemcitabine and low-dose CDDP/5-FU].
  • Patients with gallbadder cancer associated with remarkable lymph node involvement along the para-aortic region are usually excluded from therapeutic plans because of their oppressive outlook.
  • We experienced two patients with Stage IV gallbadder cancer who had undergone intra-aortic infusion chemotherapy and experienced its tumoricidal effects.
  • By keeping the tip of the catheter in the aorta at the Th 9-10 level, we intended to improve the efficiency of drug delivery to both primary lesion and para-aortic metastatic lymph nodes.
  • The anti-cancer drugs employed were gemcitabine (day 3, 9, 1,000 mg/m2/30 min) and low-dose CDDP (day 1-5, day 8-12, 5 mg/30 min) combined with 5-FU (day 1-5, day 8-12, 250 mg/24 h).
  • Day 15-21 was the treatment-free time for recovery from drug toxicities.
  • The survival periods from the induction of the treatment were 12 and 14 months, respectively.
  • Thus intra-aortic infusion chemotherapy may be beneficial for the treatment of gallbladder cancer associated with para-aortic lymph node involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aorta. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Middle Aged

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184939.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


23. Nakamoto Y, Ogata M, Yamamoto M: [A long-term survivor treated with S-1 and gemcitabine for recurrence following an operation for advanced gall bladder cancer]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1979-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survivor treated with S-1 and gemcitabine for recurrence following an operation for advanced gall bladder cancer].
  • The patient was a 75-year-old woman who had undergone an operation for T4, N0: stage IV a gall bladder cancer in May of 2003.
  • UFT was given as adjuvant chemotherapy.
  • To our knowledge, no case of a long survivor with S-1 and GEM for recurrence after a gall bladder cancer operation has been reported in the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Fatal Outcome. Female. Humans. Neoplasm Staging. Recurrence. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gall Bladder Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948268.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


24. Endo I, Masunari H, Sugita M, Morioka D, Tanaka K, Togo S, Sekido H, Yoshida T, Shimada H: [Indications for combined resection and reconstruction of the hepatic artery in biliary tract carcinoma]. Nihon Geka Gakkai Zasshi; 2001 Nov;102(11):820-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 10 years have passed since hepatic artery resection was first performed for the treatment of biliary tract cancer.
  • The safety of this procedure has been established with the introduction of the microsurgery technique.
  • However, the benefits of and indications for this treatment have not yet been clarified.
  • Twenty-three patients underwent vascular resection (portal vein in 7, portal vein + hepatic artery in 9, hepatic artery in 7) among 114 resected patients with biliary tract cancer in our institution.
  • The curative resection rate was 88.9% in hilar bile duct cancer.
  • Cumulative 5-year survival rates of vascular resection patients with hilar bile duct cancer, lower bile duct cancer, gallbladder cancer, and cholangiocarcinoma were 14.8%, 25%, 0%, and 0%, respectively.
  • On the other hand, the rates were 38.9%, 0%, 0%, and 0%, in the stage III + IV patients who did not undergo vascular resection.
  • The longest survival period among patients with hilar bile duct cancer and lower bile duct cancer was 85 months and 65 months, respectively, whereas it was 15 months in gallbladder cancer and 20 months in cholangiocarcinoma patients.
  • No hilar bile duct cancer patient who survived for more than 3 years had lymph node metastasis.
  • The longest surviving cholangiocarcinoma patient has received adjuvant chemotherapy consisting of 5-fluorouracil and cisplatin.
  • It is concluded that patients with hilar bile duct cancer are good candidates for vascular resection.
  • Adjuvant chemotherapy should be administered to gallbladder cancer and cholangiocarcinoma patients, because vascular resection alone does not result in prolongation of life in these patients.
  • [MeSH-minor] Aged. Anastomosis, Surgical / methods. Chemotherapy, Adjuvant. Cholangiocarcinoma / mortality. Cholangiocarcinoma / surgery. Female. Gallbladder Neoplasms / mortality. Gallbladder Neoplasms / surgery. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11729649.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Abou-Alfa GK, Rowinsky EK, Patt YZ, Schwartz GK, Kelsen DP, Sharma S, Siegel E, Becerra CR, Eckhardt SG, Feit K, De Jager R, O'Reilly EM: A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am J Clin Oncol; 2005 Aug;28(4):334-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma.
  • METHODS: Patients with 0 to 1 prior chemotherapy regimens, adequate major organ function, and metastatic disease were eligible.
  • Exatecan was administered at a dose of 0.5 mg/m2 IV over 30 minutes daily on days 1 through 5 every 21 days.
  • A Simon optimal 2-stage design was employed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Camptothecin / analogs & derivatives. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Drug Administration Schedule. Female. Half-Life. Humans. Male. Middle Aged. Survival Rate. Topoisomerase I Inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062073.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Topoisomerase I Inhibitors; 0 / exatecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement